From the monthly archives: June 2012

DAKO not the right partner for the NGAL-Test

By On 25. June 2012 · Leave a Comment · In BioPorto

DAKO (now a part of AGILENT )  and Bioporto entered into a distribution  Agreement The NGAL Test  late 2010, starting from january 2011. This weekend I was at a Party and ended up talking to  a former DAKO employee.

Eventually we discussed the poor outcome of the Agreement, his (biased) view was that it had […]

Continue Reading →

NGAL, AKI after Liver Transplantations

By On 20. June 2012 · Leave a Comment · In BioPorto

NGAL measurement has a role to play in detecting AKI after  Liver Transplantations. In a very interesting article found on Bioporto.com Taiwanese doctos have looked into that relationship.

Measurements in Taiwan are done using the NGALTest from BioPort (amongst others)

Concentrations of sCr and urinary creatinine (uCr) were measured using the Jaffe kinetic method […]

Continue Reading →

A mixed summer cocktail of NGAL news

By On 20. June 2012 · Leave a Comment · In BioPorto

While waiting for News on a distribution Agreement for BioPorto’s NGAL Test, our readers and supporters are eagerly crawling the net.

The last couple of days have seen interesting news from – amongst other developing countries – Romania, Canada, Abbottistan,

The canadian article deals with RRT (renal transplant) , and the role of biomarkers in […]

Continue Reading →

Spectrum chart update

By On 19. June 2012 · Leave a Comment · In Spectrum

For den forsigtige investor kan der godt være en god deal i at hjemtage ldit gevinst her på toppen af trendlinjen og håbe på genkøb på bunden af den opadgående trendlinje.

Continue Reading →

En del af chatten omkring dommen

By On 16. June 2012 · Leave a Comment · In BioPorto

jeg har redigeret lidt i gårsdagens chat – men for BioPorto interesserede og informationssøgende er der lidt god info hist og pist: admin 8:16 AM Med få ord… Hvis vi vinder burde Phadia være væk, og Bioporto er de eneste med et patent på området. Det er godt. Som i meget godt. Hvis de taber […]

Continue Reading →

TopoTarget chat (den første)

By On 16. June 2012 · Leave a Comment · In Topotarget

Fredag eftermiddag kom TopoTarget rigtig i chatten – der er synes jeg god info at hente: Henning 3:56 PM Nej, jeg har kun de aktier, der kilder mest i maven, altså small cap, specielt Bioporto, Topo og Exiqon samt lidt forskellige, herunder cBrain. ndrs 3:56 PM Jeg er selv helt ude af alt bortset fra […]

Continue Reading →

Bioporto VS Phadia. Dommen fra Sø&Handelsretten.

By On 15. June 2012 · Leave a Comment · In BioPorto

Udskrift fra Sø&Handelsrettens Dombog.

DOM Afsagt den 15. juni 2012 T-9-07 BioPorto Diagnostics A/S (Advokat Morten Bruus) mod Phadia A/S (Advokat Peter-Ulrik Plesner)

 

Continue Reading →

NGAL and diabetes mellitus study

By On 15. June 2012 · 1 Comment · In BioPorto

This recent study looks into the correlation between NGAL levels and diabetes mellitus (or plain diabetes 2)

The daily news – Research on Early Detection of Kidney Damage and Coagulation Abnormalities in Type 2 Diabetes Nephronpathy

http://www.res-medical.com/endocrine-glands/103872

Concluding that: “We  found urine NGAL has risen in DM patients,so these Could reflect early renal tubular damage in diabetes,and […]

Continue Reading →

NGAL BioPorto and Phadia in Medwatch.dk

By On 15. June 2012 · Leave a Comment · In BioPorto

NGAL – For the benefit of our esteemed readers from overseas- here is a transcript of todays article on BioPorto and Phadia in medwatch.dk

http://medwatch.dk/secure/Medicinal___Biotek/article4723291.ece

The relief and joy was measurable in the voice of Bioporto’s  CEO (Thea Olesen) when MedWatch caught her on the phone, shortly after the danish Sea & Maritime Court […]

Continue Reading →

BioPorto vs Phadia … BioPorto won 2-0

By On 15. June 2012 · Leave a Comment · In BioPorto

Today the judges of Sø & Handelsretten gave their verdict in the long lasting case of Phadia vs Bioporto.

The case has been hanging like a dead albatros around BioPorto’s neck (the ancient mariner), to some extent prohibiting BioPorto from entering distribution Agreements with major (global) distributors.

Thankfully this is now a closed Chapter. […]

Continue Reading →

NGAL the role in contrast induced nepropathy CIN

By On 14. June 2012 · Leave a Comment · In BioPorto

CIN – Contrast Induced Nepropathy is the only type of AKI where you can pinpoint the excact time of the injury.

Dr Mohammad Khatami of the Iranian Tehran University  has witten an interesting paper on CIN, causes, markers, therapies and future options.

As stated above CIN is the ONLY type of AKI where you have the […]

Continue Reading →
Set your Twitter account name in your settings to use the TwitterBar Section.